Overview

• The case, Makaveev v. RxSight, Inc., No. 25-cv-01596, is pending in the U.S. District Court for the Central District of California.
• The complaint alleges RxSight and certain executives overstated product demand, concealed "adoption challenges," and left investors with guidance the company was unlikely to meet.
• The putative class period spans November 7, 2024 through July 8, 2025 for purchasers of RxSight securities.
• On July 8, 2025, RxSight disclosed preliminary Q2 declines in LDD sales and LAL utilization and cut full-year guidance by about $42.5 million at the midpoint, with the CEO attributing issues to adoption challenges.
• RxSight shares fell roughly 38% to $7.95 on July 9 on heavy trading, and multiple plaintiff firms are vying to represent investors in the lead-plaintiff selection process.